繁體 | CN | EN
Audit
Committee
Nomination
Committee
Remuneration
Committee
Strategic
Committee
Executive
Directors
Non-executive
Directors
Independent
Non-executive
Directors
Dr. Zhi HONG
Mr. Yongqing LUO
Mr. Robert Taylor NELSEN
Dr. Martin J MURPHY JR
 
Ms. Grace Hui TANG
 
Mr. Yiu Wa Alec TSUI
 
Mr. Gregg Huber ALTON
 
Dr. Axel BOUCHON
 
= Chairperson    = Member





Zhi HONG, Ph.D.
Zhi HONG, Ph.D.

Executive Director, Chairman of the Board and Chief Executive Officer

Li Yan, M.D., Ph.D.
Yongqing LUO
(Rogers LUO)

Executive Director, President and General Manager, Greater China Chief Executive Officer of TSB Therapeutics

Li Yan, M.D., Ph.D.
Li Yan, M.D., Ph.D.

Chief Medical Officer

Li Yan, M.D., Ph.D.
Ankang Li, Ph.D., J.D., CFA

Chief Financial and Strategy Officer

Lianhong Xu, Ph.D.
Lianhong Xu, Ph.D.

Senior Vice President,
Head of Medicinal Chemistry

Qing Zhu, Ph.D.
Qing Zhu, Ph.D.

Senior Vice President,
Head of Biopharmaceutical Research

Coy Stout

Senior Vice President,
Head of U.S. Market Access and Patient Advocacy

David Margolis, M.D., MPH

Vice President,
Head of Infectious Diseases Therapy Area

Karen D. Neuendorff

Chief People Officer and Head of Human Resources

  • List of Directors and Their Roles and Functions

  • Terms of Reference of Strategy Committee

  • Terms of Reference of The Audit Committee

  • Terms of Reference of The Nomination Committee

  • Terms of Reference of The Remuneration Committee

  • Amended and Restated Memorandum and Articles of Association

  • Board Diversity Policy

  • Shareholders’ Communication Policy

  • Procedures for Shareholders to Propose a Person for Election as a Director of the Company

×

Zhi Hong, Ph.D.
Dr. Zhi HONG
Executive Director

Dr. Hong co-founded Brii Bio in 2018 and has served as Chief Executive Officer since the company’s inception. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline's (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK's comeback and success in HIV and Infectious Diseases medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay and Triumeq. Dr. Hong was the champion of GSK's effort in long-acting HIV treatment and prevention therapies resulting in the first approval of Cabenuva.

Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./E.U. governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He helped to create GSK's Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of ViiV Healthcare.

×

Mr. Yongqing LUO
Executive Director

Mr. Luo has more than 25 years of experience in healthcare industry. Prior joining Brii, he was Vice President and General Manager of Gilead China. Mr. Luo led the development, regulatory application and launch of eight innovative products, gaining rapid access across China. He also led the team and established a unique business model encompassing science, commercialization and patient access. Prior to joining Gilead, he oversaw sales, marketing, government affairs and market access functions for leading pharmaceutical companies including Roche and Novartis. While in those positions, he led the launches of several high-profile medicines, and pioneered new patient access solutions through collaborations with private insurance companies and government agencies.

Mr. Luo received his medical education from Xiangya School of Medicine, Central-South University, serving three years as a surgeon at St. Luke’s Hospital, Shanghai. He also holds an EMBA from China Europe International Business School.

×

Mr. Robert Taylor NELSEN
Non-executive Director

Mr, Robert Taylor NELSEN, was appointed as a Director on June 22, 2018 and re-designated as a non-executive Director on March 24, 2021. Since November 2018, February 2019 and February 2019, he has been serving as a director of Brii HK, Brii Shanghai and Brii Beijing, respectively.

Since 1994, Mr. Nelsen has been serving as a co-founder and managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, and he has played a significant role in the early sourcing, financing, and development of more than 30 biopharmaceutical companies. In addition, Mr. Nelsen currently holds directorships in multiple biopharmaceutical companies listed on the NASDAQ stock exchange or the Stock Exchange. As a board member, Mr. Nelsen would generally attend board meetings to provide guidance to company strategy and discuss pertinent issues such as fundraising, recruiting, R&D and status of clinical programs. Mr. Nelsen also previously served as a trustee of Fred Hutchinson Cancer Research Center.

Mr. Nelsen obtained his Bachelor of Science with majors in Economics and Biology from the University of Puget Sound in the United States in June 1985 and a Master of Business Administration from the University of Chicago in the United States in June 1987.

×

Dr. Axel BOUCHON
Non-executive Director

Dr. Bouchon has served as the chairman of BrainLuxury Inc, a consumer company engaged in the nutritional supplements business in the United States, since January 2021; chairman of Brain Games Corporation, a consumer company engaged in the neurotechnology business in the United States, since January 2020; and Geschäftsführer (chief executive officer) of AMLOne UG (limited liability), an investment and consulting company in Germany, since its founding in July 2016.

From January 2015 to June 2019, Dr. Bouchon was at Bayer AG, a company specializing in pharmaceutical, consumer health and agricultural products listed on the German Stock Exchange (stock code: BAYRY). Dr. Bouchon was the Head of Leaps by Bayer (former Bayer Lifescience Center). Between November 2013 and December 2014, Dr. Bouchon was Serial CEO of Moderna Ventures and a member of the Moderna Therapeutics, Inc. Executive Committee. Moderna Therapeutics, Inc. is a pharmaceutical and biotechnology company listed on the NASDAQ Stock Exchange in the United States (stock code: MRNA).

Dr. Bouchon obtained his diploma in Biochemistry, and a Doctor of Natural Sciences from Eberhard Karls University of Tübingen in Germany in November 1998 and July 2002 respectively.

×

Dr. Martin J Murphy JR
Independent Non-executive Director

Dr. Murphy Jr has been serving as the chairman and the chief executive officer of AlphaMed Consulting, Inc., a biomedical consulting company since March 2003. He provides executive consultation on cancer drug development, clinical trial design, key thought leader identification and strategic analysis of big data and artificial intelligence to both corporate executives as well as cancer drug developers.

Dr. Murphy Jr was the founding chief executive officer of CEO Roundtable on Cancer, a non-profit organization that works to develop and implement initiatives that reduce the risk of cancer, from August 2000 to January 2020. He received the Charles A. Sanders Life Sciences Award presented by Life Sciences Consortium and CEO Roundtable on Cancer in November 2019. Dr. Murphy Jr has been the Emeritus Director of the CEO Roundtable on Cancer since January 2021. He has also been a fellow of the American Society of Clinical Oncology since 2013.

Dr. Murphy Jr was awarded a Master of Science in Biology from New York University in the United States in February 1967, a Ph.D in Biology from New York University in the United States in June 1969 and a Doctor of Medical Science (honoris causa) from Queen’s University of Belfast in the United Kingdom in July 2009.

×

Ms. Grace Hui TANG
Independent Non-executive Director

Ms. Grace Hui TANG, has been serving as a director and member of audit committee of Textainer Group Holdings Limited, (stock code: TGH) since July 2020. She has been serving as a professor and interviewer of Peking University’s Guanghua School of Management, and she is responsible for teaching graduate accounting program and interviewing MBA candidates since September 2018. Ms. Tang held several positions in China, Hong Kong and US Silicon Valley offices in PricewaterhouseCoopers, an accounting firm, from March 1990 to June 2020 and her last position therein was partner in the assurance department in China office and she was responsible for overseeing audit work.

Ms. Tang obtained her Bachelor of Science with majors in Accounting from the University of Utah in the United States in June 1982 and a Master of Business from Utah State University in the United States in June 1984. Ms. Tang has been a certified public accountant of the California Board of Accountancy of the United States since December 1993. She has been a certified public accountant of the Hong Kong Institute of Certified Public Accountants since July 1995. She has been a fellow of the Hong Kong Institute of Certified Public Accountants since March 2003.

×

Mr. Yiu Wa Alec TSUI
Independent Non-executive Director

Mr. Yiu Wa Alec TSUI has over 40 years of experience in finance and administration, corporate and strategic planning, information technology and human resources management.

Mr. Tsui has been an independent non-executive director of a number of companies listed on the Stock Exchange, namely, COSCO Shipping International (Hong Kong) Co., Ltd. (stock code: 517) since February 2004, Pacific Online Limited (stock code: 543) since November 2007 and Hua Medicine (stock code: 2552) since September 2018. He has also been serving as the independent director of a number of companies listed on NASDAQ Stock Exchange in the United States, namely, ATA Creativity Global (stock code: AACG) since January 2008 and Melco Resorts & Entertainment Limited (stock code: MLCO) since December 2006. Since August 2000, he has also been an independent non-executive director of Industrial & Commercial Bank of China (Asia) Limited (stock code: 349) and was delisted with effect from December 21, 2010. In addition, Mr. Tsui has been serving as a director to WAG Worldsec Management Consultancy Limited, a consulting company, and he is responsible for setting the strategic direction of the company and the day-to-day management of the company since April 2006. Mr. Tsui also served as independent non-executive directors in various other Hong Kong listed companies previously.

Mr. Tsui was admitted as a member of the Hong Kong Securities and Investment Institute in November 1998 and became the senior fellow of the Hong Kong Securities and Investment Institute in September 2014.

Mr. Tsui obtained his Bachelor of Science in Industrial Engineering from the University of Tennessee in the United States in June 1975 and a Master of Engineering from the University of Tennessee in the United States in August 1976. He also completed the Program for Senior Managers in Government at the John F. Kennedy School of Government at Harvard University in the United States in August 1993.

×

Mr. Gregg Huber ALTON
Independent Non-executive Director

Mr. Gregg Huber ALTON has been serving as a director and member of the audit committee of Novavax, Inc., (stock code: NVAX) since November 2020 and December 2020, respectively. He has been serving as a director, the chair of the corporate governance and nominating committee as well as the audit committee, and member of the compensation committee of Corcept Therapeutics Incorporated, (stock code: CORT) since March 2020. Further, Mr. Alton has been serving as a director, member of the audit committee and the chair of the nominating and corporate governance committee of Enochian Biosciences Inc., a pharmaceuticals company listed on NASDAQ Stock Exchange (stock code: ENOB) since December 2019.

Mr. Alton held several positions in Gilead Sciences, Inc., a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: GILD) from October 1999 to January 2020, including general counsel, chief patent officer, interim chief executive officer and senior advisor of Gilead Sciences, Inc., and he was responsible for the company’s government affairs, public affairs, patient outreach and engagement initiatives, and led the company’s international commercial operations and corporate affairs groups. Mr. Alton was an associate at Cooley Godward, LLP, a law firm, between November 1993 to December 1996, and June 1998 to October 1999. He was an associate attorney at Mintz Levin P.C., a law firm, from January 1997 to May 1998.

Mr. Alton obtained his Bachelor of Arts with a major in legal studies from the University of California in Berkeley, the United States in May 1989, and a Doctor of Jurisprudence from The Leland Stanford Junior University in the United States in June 1993.Mr. Alton was also admitted as an attorney and counselor at law by the supreme court of the state of California between June 1994 and July 2019.

×